Assembly Biosciences (NASDAQ:ASMB) Posts Quarterly Earnings Results, Misses Estimates By $0.27 EPS

Key Points

• Assembly Biosciences reported a quarterly loss of $0.93 per share, missing analyst estimates by $0.27; revenue was $2.96 million versus the $9.07 million consensus.
• The stock fell 9.8% on Thursday, closing at $20.18.
• Analysts’ average rating is “Moderate Buy,” with a consensus price target of $46.50.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.27), FiscalAI reports. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The business had revenue of $2.96 million during the quarter, compared to the consensus estimate of $9.07 million.

Assembly Biosciences Trading Down 9.8%

ASMB stock traded down $2.19 during trading on Thursday, hitting $20.18. The company had a trading volume of 499,584 shares, compared to its average volume of 195,617. The business has a 50-day moving average of $23.88 and a 200-day moving average of $26.91. Assembly Biosciences has a one year low of $19.20 and a one year high of $39.71. The stock has a market cap of $410.88 million, a PE ratio of 19.78 and a beta of 1.26.

Insider Buying and Selling at Assembly Biosciences

In other Assembly Biosciences news, insider Nicole White sold 2,593 shares of the firm's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total transaction of $50,874.66. Following the completion of the transaction, the insider owned 59,257 shares in the company, valued at approximately $1,162,622.34. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Anuj Gaggar sold 2,593 shares of the business's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $19.62, for a total transaction of $50,874.66. Following the completion of the transaction, the insider owned 53,800 shares in the company, valued at $1,055,556. This trade represents a 4.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 12,115 shares of company stock valued at $237,696. 3.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ASMB shares. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a report on Tuesday, August 18th. Mizuho set a $53.00 price target on shares of Assembly Biosciences in a report on Tuesday, September 1st. UBS Group cut their price target on shares of Assembly Biosciences from $52.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, November 3rd. Zacks Research cut shares of Assembly Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Monday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Assembly Biosciences in a report on Thursday, October 15th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $46.50.

About Assembly Biosciences

Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company's pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.